Potential biomarkers for early detection of acute graft-versus-host disease

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

LOCHMANOVÁ Gabriela JEDLIČKOVÁ Lenka POTĚŠIL David TOMANCOVÁ Alexandra VERNER Jan POSPÍŠILOVÁ Šárka DOUBEK Michael MAYER Jiří ZDRÁHAL Zbyněk

Rok publikování 2012
Druh Článek v odborném periodiku
Časopis / Zdroj Proteomics : clinical applications.
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://www.ncbi.nlm.nih.gov/pubmed/22927351
Doi http://dx.doi.org/10.1002/prca.201100104
Obor Onkologie a hematologie
Klíčová slova BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; C-REACTIVE PROTEIN; SERUM CYTOKINE LEVELS; NECROSIS-FACTOR-ALPHA; ACUTE GVHD; SOLUBLE INTERLEUKIN-2-RECEPTOR; QUANTITATIVE PROTEOMICS; MAJOR COMPLICATIONS; PLASMA BIOMARKERS
Přiložené soubory
Popis Acute graft-versus-host disease (aGVHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HCT), resulting in considerable morbidity and mortality. Currently, the diagnosis of aGVHD is largely made based on clinical parameters and invasive biopsies. For the past 20 years, researchers have been trying to find reliable biomarkers to enable early and accurate diagnosis of aGVHD. Although a number of potential aGVHD biomarkers have been published, as yet, no validated diagnostic test is available. Proteomics encompasses a broad range of rapidly developing technologies, which have shown tremendous promise for early detection of aGVHD. In this article, we review the current state of aGVHD biomarker discovery, provide a summary of the key proteins of interest and the most common analytical procedures for the clinic, as well as outlining the significant challenges faced in their use.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.